Home > others & > Deferasirox

Deferasirox

地拉罗司,CGP-72670,ICL-670,CGP 72670,CGP72670,ICL670,ICL 670,

Deferasirox是口服铁螯合剂。

目录号
EY1730
EY1730
EY1730
EY1730
纯度
99.13%
99.13%
99.13%
99.13%
规格
5 mg
10 mg
50 mg
100 mg
原价
750
1310
4812
7690
售价
750
1310
4812
7690
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Deferasirox is a rationally-designed oral iron chelator.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Ibrahim AS, et al. J Clin Invest, 2007, 117(9), 2649-2657.

    分子式
    C21H15N3O4    		 分子量
    373.36    		 CAS号
    201530-41-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    75 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    2 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00845871 Transfusional Hemosiderosis Drug: deferasirox: Novartis Pharmaceuticals|Novartis Phase 4 2009-03-01 2014-05-07
    NCT01724138 thalassemia Major Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 4 2013-06-01 2014-08-21
    NCT01159067 Iron Overload|Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Small Lymphocytic Lymphoma Drug: deferasirox City of Hope Medical Center 2010-07-01 2012-07-16
    NCT00560820 thalassemia|Transfusional Iron Overload Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 1 2007-09-01 2016-06-17
    NCT00303329 Anemia|Hemosiderosis Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 2 2004-03-01 2011-04-15
    NCT00171301 Beta-thalassemia Major|Hemosiderosis|Iron Overload|Rare Anemia Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 4 2005-06-01 2011-08-28
    NCT01948817 Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 2 2014-02-01 2014-01-15
    NCT00432627 Hepatic Impairment Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 1 2006-12-01 2016-04-20
    NCT01709838 Non-transfusion Dependent Thalassemia Drug: ICL670 deferasirox Novartis Pharmaceuticals|Novartis Phase 4 2012-12-01 2016-07-09
    NCT01459718 Transfusion-dependent thalassemia Patients|Cardiac Iron Overload Drug: Deferasirox|Drug: Deferasirox + Deferoxamine Novartis Pharmaceuticals|Novartis Phase 2 2011-01-01 2015-02-09
    NCT00631163 Chronic Anemia|Transfusional Hemosiderosis Drug: Deferasirox (ICL670) Novartis Pharmaceuticals|Novartis Phase 2 2007-10-01 2016-11-15
    NCT00481143 Myelodysplastic Syndromes|Transfusion Dependent Iron Overload Drug: ICL670/Deferasirox Novartis Pharmaceuticals|Novartis Phase 4 2007-05-01 2016-11-16
    NCT00171210 Transfusional Iron Overload in thalassemia Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 3 2004-10-01 2011-05-24
    NCT00564941 Myelodysplastic Syndromes|Beta-Thalassemia Drug: deferasirox Novartis Pharmaceuticals|Novartis Phase 4 2007-12-01 2017-02-22
    NCT00390858 Transfusional Iron Overload|thalassemia Major|Pediatric Rare Anemia Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 2 2003-09-01 2017-02-12
    NCT01284946 Porphyria Cutanea Tarda Drug: Exjade Assistance Publique - H么pitaux de Paris|Association pour l'Etude des Fonctions Digestives (AEFD) Phase 2 2011-01-01 2011-01-26
    NCT01250951 Myelodysplastic Syndrome|Thalassemia Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 4 2009-12-01 2016-12-08
    NCT00469560 Myelodysplastic Syndromes|Hemosiderosis Drug: Deferasirox Gruppo Italiano Malattie EMatologiche dell'Adulto Phase 3 2007-06-01 2016-11-21
    NCT02993224 Transfusion-dependent Thalassemia (TDT) and Non-transfusion-dependent Thalassemia (NTDT) Drug: deferasirox dispersable tablet (DT)|Drug: deferasirox film coated tablet (FCT) Novartis Pharmaceuticals|Novartis Phase 2 2017-04-30 2017-03-21
    NCT01892644 Hemochromatosis|Myelodysplastic Syndromes Drug: Deferasirox|Other: Venesection|Drug: Deferasirox Haukeland University Hospital|Novartis Phase 2 2013-05-01 2017-01-20
    NCT00602446 Breast Cancer|Iron Overload|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer Drug: deferasirox Masonic Cancer Center, University of Minnesota Phase 2 2007-08-01 2012-11-06
    NCT02038816 Myelodysplastic Syndromes Drug: Deferasirox + Azacitidine|Drug: Azacitidine Sunnybrook Health Sciences Centre|Novartis Phase 2 2014-03-01 2014-01-15
    NCT00447694 Beta-thalassemia|Iron Overload Drug: Deferasirox Novartis Phase 2 2006-02-01 2016-09-22
    NCT00379483 Transfusional Iron Overload Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 2 2002-07-01 2015-03-18
    NCT00235391 Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Myelofibrosis Drug: Deferasirox Novartis Pharmaceuticals|Novartis Phase 3 2005-10-01 2011-06-03

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：